Safety and efficacy of cell therapy in psorisis
- Conditions
- Psoriasis.Psoriasis
- Registration Number
- IRCT20080901001159N29
- Lead Sponsor
- Skin and Stem cell Research Center of Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Chronic plaque psoriasis for at least 6 months plaque Mild to severity of moderate (grade 1-3) PASI 3-12 No response to standard treatments No incidence of new lesion or increase in size of previous lesions during past 3 months
Other types of psoriasis include pustular, erythrodermic, gotate, and drug induced Immunosuppressive drugs over the past 4 weeks or topical medications other than moisturizing lotions in the 2 past weeks Severe underlying disease (including liver, kidney and heart failure), increased liver enzymes more than 3 times normal and creatinine more than 2 high and uncontrolled blood pressure Pregnancy or lactation diabetes mellitus Hepatitis B, C or HIV Patients with immunodeficiency Patients with malignancy Disabling disease Systemic or injection site infection
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain. Timepoint: intervention start date up to 3 months. Method of measurement: Pain intensity scale.;Redness severity. Timepoint: intervention start date up to 3 months. Method of measurement: Physical examination.
- Secondary Outcome Measures
Name Time Method esion severity (grade 1-3). Timepoint: Before intervention, every week up to 1 month, and every month up to 3 months. Method of measurement: evaluator assessment.